Is measurement of endothelial dysfunction clinically useful?

European Journal of Clinical Investigation

Volumn 29, Issue 6, 1999, Pages 459-461

  Stehouwer, C D A ^a,b,c  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROSIS; BLOOD VESSEL TONE; EDITORIAL; ENDOTHELIUM LESION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MEASUREMENT; PRIORITY JOURNAL; RISK FACTOR;

CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; RISK FACTORS;

EID: 0032971963     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1999.00497.x     Document Type: Editorial

References (20)

1. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-5.
2. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-8.
3. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-9.
4. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
5. Montalescot G, Philippe F, Ankri A, el al., for the French investigators of the ESSENCE trial. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Circulation 1998; 98: 294-9.
6. Thögersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Circulation 1998; 98: 2241-7.
7. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, den Ottolander GJH. Albuminuria, cardiovascular disease and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-3.
8. Deckert T, Yokoyama H, Mathiesen E, et al. Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. Br Med J 1996; 312: 871-4.
9. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in non-insulin-dependent diabetes mellitus. Diabetes 1995; 44: 1301-9.
10. Jager A, Kostense PJ, Ruhé HG, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular disease and all-cause mortality, especially among hypertensive subjects. Arterioscler Thromb Vasc Biol 1999; (in press).
11. Blann AD, Taberner DA. A reliable marker of endothelial dysfunction does it exist? Er J Haematol 1995; 90: 244-8.
12. Stehouwer CDA, Lambert J, Donker AJM, van Hinsbergh VWM. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34:55-68.
13. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996; 97: 22-8.
14. Faggiotto A, Poli A, Catapano AL. Antioxidants and coronary artery disease. Curr Opin Lipidol 1998; 9: 541-9.
15. Morris SJ, Shore AC, Tooke JE. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with non-insulin-dependent diabetes mellitus. Diabetologia 1995; 38: 1337-44.
16. Pinkney JH, Stehouwer CDA, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997; 46 (Suppl. 2):9-13.
17. Celermajer DS. Endothelial dysfunction does it matter? Is it reversible? J Am Coll Cardiol 1997; 30: 325-33.
18. Stehouwer CDA, Yudkin JS, Fioretto P, Nosadini R. How heterogeneous is microalbuminuria? The case for 'benign' and 'malignant' microalbuminuria. Nephrol Dial Transplant 1998; 13: 2751-4.
19. Blum A, Cannon RO. Effects of oestrogens and selective oestrogen receptor modulators on serum lipoproteins and vascular function. Curr Opin Lipidol 1998; 9: 575-86.
20. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.